Burt Nabors

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

68h-index19.2kcitations622works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(367), Cancer, Hypoxia, and Metabolism(89), Brain Metastases and Treatment(68), Radiopharmaceutical Chemistry and Applications(51), Radiomics and Machine Learning in Medical Imaging(43)

Publications617 total

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Journal of Clinical Oncology·2025Open Access
10001-NT-1 ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma
Neuro-Oncology Advances·2025Open Access
Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma
JAMA Network Open·2025· 1 citedOpen Access
CTNI-57. PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) IN PATIENTS WITH CNS LYMPHOMA
Neuro-Oncology·2025Open Access
INNV-04. Association of proton pump inhibitor use with outcome of patients with newly diagnosed glioblastoma
Neuro-Oncology·2025Open Access
IMG-89. Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
Neuro-Oncology·2025Open Access
TMOD-08. Modeling low-grade astrocytoma by genetic engineering of brain organoids
Neuro-Oncology·2025Open Access
IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
Neuro-Oncology·2025Open Access
DDDR-69. Discovery, validation and deployment of a molecular signature of vulnerability to GB13 in an early stage GBM clinical trial
Neuro-Oncology·2025Open Access
TMIC-119. Evaluating the Impact of Tumor-Secreted Fibronectin-1 on the Perivascular Niche (PVN) and Glioblastoma Malignancy
Neuro-Oncology·2025Open Access
CTIM-17. INB-200: PHASE 1 STUDY AND CHARACTERIZATION OF GENE-MODIFIED AUTOLOGOUS GAMMA-DELTA (ΓΔ) T CELLS IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS RECEIVING MAINTENANCE TEMOZOLOMIDE (TMZ)
Neuro-Oncology·2025Open Access
CTNI-56. PLANNED GLUCARPIDASE FOR CNS LYMPHOMA PATIENTS AT HIGH RISK OF METHOTREXATE (MTX) TOXICITY
Neuro-Oncology·2025Open Access
IMG-133. System L amino acid ([F-18]FET) and hypoxia ([F-18]FMISO) PET/MRI to assess early response after completion of radiation therapy in high grade glioma
Neuro-Oncology·2025Open Access
CTNI-58. UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA
Neuro-Oncology·2025Open Access
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology·2025· 6 cited
Survival outcomes associated with antidepressant use in glioblastoma: a cohort study
Journal of Neuro-Oncology·2025Open Access
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Neuro-Oncology·2025
P17.15.A ASSOCIATION OF PROTON PUMP INHIBITOR USE WITH OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology·2025Open Access
OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL
Neuro-Oncology·2025Open Access
Successful use of response leads to ONC201 approval
Neuro-Oncology·2025
page 1 of 31Next →

Frequent Co-authors

David A. Reardon(13), Patrick Y. Wen(11), G. Yancey Gillespie(10), Tom Mikkelsen(9), Jana Portnow(8), Nicholas Butowski(8), Roger Stupp(7), Michael Weller(7), Peter H. King(7), Matthias Holdhoff(7), Larry Junck(7), Maciej M. Mrugała(7), Stuart A. Grossman(7), Mark R. Gilbert(7), Monika E. Hegi(6), James Perry(6), Martin J. van den Bent(6), Jay S. Loeffler(6), Dennis C. Shrieve(6), Timothy F. Cloughesy(5)